These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10113009)

  • 1. Cost of innovation in the pharmaceutical industry.
    DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
    J Health Econ; 1991 Jul; 10(2):107-42. PubMed ID: 10113009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Innovation in the pharmaceutical industry: New estimates of R&D costs.
    DiMasi JA; Grabowski HG; Hansen RW
    J Health Econ; 2016 May; 47():20-33. PubMed ID: 26928437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.
    DiMasi JA; Hansen RW; Grabowski HG; Lasagna L
    Pharmacoeconomics; 1995 Feb; 7(2):152-69. PubMed ID: 10155302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costing drug development.
    Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
    [No Abstract]   [Full Text] [Related]  

  • 6. New estimates of drug development costs.
    Frank RG
    J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug development costs when financial risk is measured using the Fama-French three-factor model.
    Vernon JA; Golec JH; Dimasi JA
    Health Econ; 2010 Aug; 19(8):1002-5. PubMed ID: 19655335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug costs: research and development costs: the great illusion.
    Prescrire Int; 2004 Feb; 13(69):32-6. PubMed ID: 15055226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research activity on systemic contraceptive drugs by the U.S. pharmaceutical industry, 1963-1976.
    DiRaddo J; Wardell WM
    Contraception; 1981 Apr; 23(4):345-65. PubMed ID: 7273757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rising research and development costs for new drugs in a cost containment environment.
    DiMasi JA
    Pharmacoeconomics; 1992; 1(Suppl 1):13-20. PubMed ID: 10146926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018.
    Wouters OJ; McKee M; Luyten J
    JAMA; 2020 Mar; 323(9):844-853. PubMed ID: 32125404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The value of improving the productivity of the drug development process: faster times and better decisions.
    DiMasi JA
    Pharmacoeconomics; 2002; 20 Suppl 3():1-10. PubMed ID: 12457421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drug development during and after a period of regulatory change: clinical research activity of major United States pharmaceutical firms, 1958 to 1979.
    May MS; Wardell WM; Lasagna L
    Clin Pharmacol Ther; 1983 Jun; 33(6):691-700. PubMed ID: 6851401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Returns to R&D on new drug introductions in the 1980s.
    Grabowski HG; Vernon JM
    J Health Econ; 1994 Dec; 13(4):383-406. PubMed ID: 10140531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019.
    Galkina Cleary E; Jackson MJ; Zhou EW; Ledley FD
    JAMA Health Forum; 2023 Apr; 4(4):e230511. PubMed ID: 37115539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opinion: development of new drugs is still a risky business.
    Franks B
    N J Med; 2002; 99(1-2):60, 59. PubMed ID: 15326736
    [No Abstract]   [Full Text] [Related]  

  • 17. Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research.
    Cockburn IM; Henderson RM
    J Health Econ; 2001 Nov; 20(6):1033-57. PubMed ID: 11758047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotech blockbusters consolidate markets.
    Lawrence S
    Nat Biotechnol; 2006 Dec; 24(12):1466. PubMed ID: 17160033
    [No Abstract]   [Full Text] [Related]  

  • 19. New drug development by United States pharmaceutical firms with analyses of trends in the acquisition and origin of drug candidates, 1963-1979.
    Wardell WM; May MS; Trimble AG
    Clin Pharmacol Ther; 1982 Oct; 32(4):407-17. PubMed ID: 7116754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rising costs hold up drug discovery.
    Miller HI
    Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.